抗体治療薬市場：フォーマット、投与経路、供給源、疾患領域、用途、エンドユーザー別-2025-2030年世界予測

抗体治療薬市場の2024年の市場規模は2,580億1,000万米ドルで、2025年には2,895億1,000万米ドル、CAGR12.45%で成長し、2030年には5,218億1,000万米ドルに達すると予測されています。

抗体治療薬は、画期的な科学と比類なき臨床的可能性が融合した、現代医学の中で最もダイナミックな分野の一つです。本エグゼクティブサマリーでは、市場の進化、現在の動向、近年の抗体治療薬情勢を決定づけた競合力学について詳しく解説します。バイオテクノロジーの開発により、特異性の高い治療法の開発が可能になり、さまざまな疾患の治療手法に革命が起きています。研究者や業界の専門家は、患者の転帰を改善するだけでなく、薬事規制や投資戦略をも変革するイノベーションにますます注目しています。このような革新的な治療法への道のりは、数十年にわたる厳密な調査、戦略的パートナーシップ、急速な技術進歩によって、総体として次世代治療への道が切り開かれてきたことを物語っています。市場が個別化医療へとシフトする中、抗体フラグメント、二重特異性抗体、モノクローナル抗体、ポリクローナル抗体の戦略的展開は、臨床と商業的成功の両方に大きな影響を及ぼします。さらに、製造プロセス、投与経路、患者中心のイノベーションなどの要因が、この分野を前進させ続けています。本サマリーは、業界の利害関係者に対し、科学的イノベーションと市場の要請を結びつける明確で詳細な物語を提供し、意思決定者が抗体治療薬の現状と将来の方向性の両方について十分な情報を得られるようにすることを目的としています。

抗体治療薬市場の変革

近年、画期的なイノベーションと進化する市場ニーズにより、抗体治療薬セクターは大きな変化を遂げています。従来のパラダイムは、治療薬の有効性と安全性プロファイルを向上させる新規技術と革新的な製造方法の統合によって再構築されました。研究開発努力は精密医療にますます合致し、副作用を最小限に抑えながら治療成果を最適化する標的介入を可能にしています。がん、自己免疫疾患、その他の慢性疾患などの領域で、タイムリーな治療ソリューションの重要な必要性が当局に認識されるにつれ、規制の枠組みも大幅に変更され、新製品の導入が加速しています。業界は統合と戦略的再編成を経験し、既存企業は機敏な経営モデルを採用し、新規参入企業は破壊的技術を活用しています。資金調達の仕組みや官民パートナーシップは、この進化する情勢の背景にある勢いをさらに際立たせています。臨床パイプラインが拡大し、治療モダリティの多様性が増すにつれ、利害関係者は価値提案、市場参入戦略、長期的な投資視点を見直す必要に迫られています。この変革期は、科学的専門家と市場戦略家との活発なコラボレーションによって特徴付けられ、イノベーション・サイクルの加速とトランスレーショナルな成功の向上につながります。このようなダイナミックな環境の結果、抗体医薬は医学の進歩の最前線に立ち続け、競合が激しくペースの速い業界で新たな道を切り開くことになります。

抗体治療薬の主要なセグメントに関する洞察

抗体治療薬市場を詳細に評価することで、現在の動向と成長機会を理解する上で重要なセグメンテーションの洞察が明らかになります。市場力学をフォーマットの観点から研究すると、抗体フラグメント、二重特異性抗体、モノクローナル抗体、ポリクローナル抗体にまたがる詳細な分析が観察され、それぞれが治療効果と臨床的差別化に独自に寄与しています。投与経路に基づく評価では、静脈内投与と皮下投与が明確に比較され、患者の利便性とバイオアベイラビリティを考慮した治療法の選択がいかに重要であるかが強調されています。さらに、投与源のセグメンテーションは、洞察に新たな層を加えます。キメラ抗体、ヒト抗体、ヒト化抗体を検討することで、分子工学が免疫原性や治療成績にどのような影響を与えたかを評価することができます。自己免疫疾患や炎症性疾患から血液学、免疫学、神経学、腫瘍学、骨学に至るまで、対象となる疾患領域の広さは、急性および慢性疾患の治療における抗体ベースの治療法の適用範囲の広さを示しています。加えて、市場は診断、調査、治療といった用途別に分類されており、抗体技術が臨床と研究所の両方の環境をどのように向上させるかを包括的に理解することができます。セグメンテーション分析では、病院、研究機関、専門クリニックがそれぞれ独自の臨床実践や調達戦略を通じて需要を形成していることから、エンドユーザーの視点を調査することで、さらに充実した内容となっています。これらの包括的な洞察により、利害関係者は微妙な市場の現実と患者のニーズを反映した戦略を立てることができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • さまざまながんや感染症の発生率の上昇
    • 世界中で増加する創薬活動
    • 抗体治療と療法へのアクセスを促進するための政府の取り組み
  • 抑制要因
    • 製品リコールの発生に対する懸念
  • 機会
    • 抗体治療薬の臨床開発の進歩
    • 新規抗体療法および治療法の承認が進行中
  • 課題
    • さまざまな治療法に伴う不十分な有効性と副作用
• 市場セグメンテーション分析
  • フォーマット：がんの診断と治療における抗体フラグメントの重要性の高まり
  • 応用：効果的な疾病管理のための診断分野における抗体治療薬の応用拡大
  • 投与経路：静脈内投与の使用が増加している抗体治療薬
  • 出典：生体適合性のためヒト抗体の使用が増加
  • 疾患領域：感染症における抗体治療薬の使用増加
  • エンドユーザー：病院における抗体治療薬の使用法の進化
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 抗体治療薬市場フォーマット別

• 抗体フラグメント
• 二重特異性抗体
• モノクローナル抗体
• ポリクローナル抗体

第7章 抗体治療薬市場：投与経路別

• 静脈内
• 皮下

第8章 抗体治療薬市場：ソース別

• キメラ
• 人間
• 人間化

第9章 抗体治療薬市場疾患領域別

• 自己免疫疾患と炎症性疾患
• 血液学
• 免疫学
• 神経学
• 腫瘍学
• 骨学

第10章 抗体治療薬市場：用途別

• 診断
• 調査
• 治療薬

第11章 抗体治療薬市場：エンドユーザー別

• 病院
• 調査機関
• 専門クリニック

第12章 南北アメリカの抗体治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の抗体治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの抗体治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• AbCellera Biologics Inc.
• Adaptimmune Therapeutics PLC
• ADC Therapeutics SA
• Aenova Holding GmbH
• Almac Group Limited
• Amgen Inc.
• Antikor Biopharma
• Argenx SE
• Astellas Pharma Inc.
• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biogen Inc.
• BioNTech SE
• Bristol-Myers Squibb Company
• Confo Therapeutics
• DH Life Sciences, LLC
• DotBio Pte. Ltd.
• Eli Lilly and Company
• Emergent BioSolutions Inc.
• Evonik Industries AG
• F. Hoffmann-La Roche Ltd.
• GE HealthCare Technologies, Inc.
• Genmab A/S
• GlaxoSmithKline PLC
• Grifols, S.A.
• Incyte Corporation
• iTeos Therapeutics, Inc.
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Merus N.V.
• MoonLake Immunotherapeutics AG
• MorphoSys AG
• Novartis AG
• Novo Nordisk A/S
• Numab Therapeutics AG
• Pfizer Inc.
• PharmAbcine Inc.
• Pyxis Oncology, Inc.
• Regeneron Pharmaceuticals, Inc.
• SAB Biotherapeutics, Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• TRIO Pharmaceuticals Inc.
• UCB S.A.
• Xencor, Inc.

LIST OF FIGURES

• FIGURE 1. ANTIBODY THERAPEUTICS MARKET MULTI-CURRENCY
• FIGURE 2. ANTIBODY THERAPEUTICS MARKET MULTI-LANGUAGE
• FIGURE 3. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 4. ANTIBODY THERAPEUTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 54. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 57. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 86. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 88. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 89. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 92. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 94. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 95. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 195. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 197. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 198. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 219. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 221. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 222. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 225. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 226. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 227. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 228. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 285. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

The Antibody Therapeutics Market was valued at USD 258.01 billion in 2024 and is projected to grow to USD 289.51 billion in 2025, with a CAGR of 12.45%, reaching USD 521.81 billion by 2030.

Antibody therapeutics represent one of the most dynamic segments of modern medicine, merging breakthrough science with unparalleled clinical potential. This executive summary offers an in-depth exploration of market evolution, current trends, and the competitive dynamics that have defined the antibody therapeutics landscape in recent years. Advancements in biotechnology have enabled the development of highly specific therapies, revolutionizing treatment methodologies across a range of diseases. Researchers and industry experts are increasingly focusing on innovations that not only improve patient outcomes but also transform regulatory pathways and investment strategies. The journey through these transformative therapies is underscored by decades of rigorous research, strategic partnerships, and rapid technological progress that have collectively paved the way for next-generation treatments. As the market shifts toward personalized medicine, the strategic deployment of antibody fragments, bispecific antibodies, monoclonal antibodies, and polyclonal antibodies exerts a profound influence on both clinical and commercial success. Moreover, factors such as manufacturing processes, route of administration, and patient-centric innovations continue to propel this field forward. This summary is designed to provide industry stakeholders with a clear, detailed narrative that bridges scientific innovation with market imperatives, ensuring that decision-makers remain well-informed about both the current state and the future direction of antibody therapeutics.

Transformative Shifts in the Antibody Therapeutics Landscape

Recent years have witnessed profound changes within the antibody therapeutics sector, driven by breakthrough innovations and evolving market needs. The traditional paradigm has been reshaped by the integration of novel technologies and innovative production methods that enhance the efficacy and safety profiles of therapies. Research and development efforts are increasingly aligned with precision medicine, allowing for targeted interventions that optimize treatment outcomes while minimizing side effects. Regulatory frameworks have also undergone significant modifications, expediting the introduction of new products as authorities acknowledge the critical need for timely therapeutic solutions in domains such as oncology, autoimmune disorders, and other chronic diseases. The industry has experienced consolidation and strategic realignments, with established companies embracing agile operational models and new entrants capitalizing on disruptive technologies. Funding mechanisms and public-private partnerships further underscore the momentum behind this evolving landscape. As clinical pipelines expand and the diversity of treatment modalities grows, stakeholders are compelled to reassess value propositions, market entry strategies, and long-term investment perspectives. This transformative period is marked by active collaboration between scientific experts and market strategists, leading to accelerated innovation cycles and improved translational successes. The resulting dynamic environment ensures that antibody therapeutics remain at the forefront of medical progress, carving new paths in a competitive and fast-paced industry.

Key Segmentation Insights into Antibody Therapeutics

A granular evaluation of the antibody therapeutics market reveals critical segmentation insights that are central to understanding current trends and growth opportunities. When studying market dynamics from a format perspective, one observes detailed analyses spanning antibody fragments, bispecific antibodies, monoclonal antibodies, and polyclonal antibodies, each contributing uniquely to therapeutic efficacy and clinical differentiation. Assessments based on the route of administration distinctly compare intravenous delivery with subcutaneous options, highlighting how patient convenience and bioavailability considerations drive therapeutic choices. Furthermore, the source segmentation adds another layer of insight. By considering chimeric, human, and humanized antibodies, analysts can evaluate how molecular engineering has impacted immunogenicity and therapeutic performance. The scope of disease areas covered-ranging from autoimmune and inflammatory diseases to hematology, immunology, neurology, oncology, and osteology-illustrates the broad applicability of antibody-based therapies in treating both acute and chronic conditions. In addition, the market is dissected along the lines of application, which spans diagnostics, research, and therapeutics, enabling a comprehensive understanding of how antibody technologies enhance both clinical and laboratory environments. The segmentation analysis is further enriched by examining the end-user perspective, with hospitals, research institutes, and specialty clinics each shaping demand through distinctive clinical practices and procurement strategies. These comprehensive insights empower stakeholders to tailor strategies that reflect nuanced market realities and patient needs.

Based on Format, market is studied across Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, and Polyclonal Antibody.

Based on Route of Administration, market is studied across Intravenous and Subcutaneous.

Based on Source, market is studied across Chimeric, Human, and Humanized.

Based on Disease Areas, market is studied across Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, and Osteology.

Based on Application, market is studied across Diagnostics, Research, and Therapeutics.

Based on End-User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.

Regional Perspectives and Growth Opportunities in Antibody Therapeutics

The antibody therapeutics market is simultaneously influenced by global trends and localized demand, with each region presenting unique growth opportunities and challenges. Insights drawn from analyses across pivotal regions indicate that the Americas continue to lead in technology adoption and innovative clinical trials, driven by robust research infrastructure and strategic investments. Meanwhile, the combined regions of Europe, Middle East, and Africa exhibit a balanced approach to market penetration, where regulatory harmonization and diversified healthcare systems foster both innovation and accessibility. In the Asia-Pacific region, rapid economic growth, a surge in health awareness, and increased investment in biotechnology have spurred exponential market expansion, positioning it as a critical area of focus for companies seeking long-term growth. The regional insights provide an integrated view of factors such as regulatory environments, patient demographics, healthcare budgets, and infrastructural capabilities. These factors collectively determine market trajectories and influence the adoption of breakthrough therapeutic strategies. The interplay between regional economic trends and technological advancements creates a fertile ground for both incremental and transformative innovations in antibody therapeutics. A nuanced understanding of these geographic variances aids industry stakeholders in designing targeted investment strategies and localizing market entry plans that optimize regional strengths and address pertinent challenges effectively.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Strategies of Key Industry Players in Antibody Therapeutics

The competitive landscape of antibody therapeutics is characterized by a constellation of industry players that are actively shaping the future of healthcare through relentless innovation and strategic foresight. Leading organizations such as AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, and ADC Therapeutics SA have demonstrated a strong commitment to integrating next-generation technologies into their development pipelines. This trend is further reinforced by companies like Aenova Holding GmbH, Almac Group Limited, and Amgen Inc., which invest in precision manufacturing and advanced screening techniques to enhance product efficacy. Notably, strategic market responses by firms such as Antikor Biopharma, Argenx SE, and Astellas Pharma Inc. underscore the increasing importance of agile operational models and adaptive clinical strategies. Similarly, global giants like AstraZeneca PLC and Bayer AG, along with specialized entities including Baxter International Inc. and Becton, Dickinson and Company, are leveraging their expansive resources to drive forward innovations in therapeutic applications. The landscape is further diversified by players such as Bio-Rad Laboratories, Inc., Biogen Inc., and BioNTech SE, who are at the forefront of clinical research and have contributed significantly to the acceleration of novel therapies. Companies like Bristol-Myers Squibb Company, Confo Therapeutics, and DH Life Sciences, LLC, among many others, demonstrate that robust R&D investments combined with strategic collaborations are key drivers of market leadership. This assemblage of industry leaders reveals an ecosystem where established pharmaceutical titans and agile biotech innovators align to address complex clinical needs while capitalizing on emerging market trends. Their efforts not only drive competitive differentiation but also fundamentally influence how antibody therapeutics are developed and delivered globally.

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc.. Actionable Recommendations for Industry Leaders in Antibody Therapeutics

Industry stakeholders must continuously adapt to the rapidly evolving landscape of antibody therapeutics by embracing innovation and fostering cross-disciplinary collaborations. A strategic emphasis on integrating advanced biotechnological methods can streamline production and enhance drug safety profiles. Leaders are advised to invest in scalable manufacturing processes that accommodate both current demands and future pipeline expansions. Furthermore, partnerships between industry, academia, and regulatory bodies are essential to fast-track clinical trials and address potential bottlenecks in product approvals. Given the diverse segmentation analysis-spanning format, route of administration, source, disease area, application, and end-user-it is critical to tailor marketing and distribution strategies accordingly. Embracing digital transformation and leveraging real-time data analytics can also provide a competitive edge by enabling more precise forecast and adaptive decision-making. Ultimately, proactive engagement in trend-setting research, technology transfer agreements, and comprehensive market assessments will not only secure a leading position in the antibody therapeutics market but also catalyze sustained innovation and growth in a competitive environment.

Conclusion: Navigating the Future of Antibody Therapeutics

The antibody therapeutics market continues to evolve at a rapid pace, driven by groundbreaking research and a dynamic competitive environment. The comprehensive insights presented in this executive summary underscore the critical significance of adaptive strategies, robust R&D investments, and targeted regional approaches that collectively shape market trajectories. The analysis of segmentation diverse in format, route of administration, source, disease area, application, and end-user reveals a system in which every component plays a vital role in meeting clinical demands. Moreover, regional evaluations highlight how localized market dynamics, regulatory frameworks, and healthcare spending patterns can influence the broader industry outlook. Equally noteworthy is the pivotal role of key industry players whose strategic initiatives have redefined competitive boundaries and set new benchmarks for innovation. As technological advancements continue to intersect with evolving therapeutic needs, stakeholders must remain vigilant, responsive, and forward-thinking. The journey ahead promises further transformative shifts that will undoubtedly redefine the contours of modern therapeutics. These insights collectively offer a strategic roadmap for decision-makers keen on navigating the complexities of the antibody therapeutics market while leveraging emerging opportunities for sustained growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of various cancers and infectious diseases
    • 5.1.1.2. Increasing number of drug discovery activities worldwide
    • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns over incidences of product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
    • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Format: Rising significance of antibody fragments for cancer diagnostics and treatment
  • 5.2.2. Application: Expanding application of antibody therapeutics in diagnostics sector for effective disease management
  • 5.2.3. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
  • 5.2.4. Source: Increasing use of human antibodies due to its biocompatible nature
  • 5.2.5. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
  • 5.2.6. End User: Evolving usage of antibody therapeutics in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibody Therapeutics Market, by Format

• 6.1. Introduction
• 6.2. Antibody Fragment
• 6.3. Bispecific Antibody
• 6.4. Monoclonal Antibody
• 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

• 8.1. Introduction
• 8.2. Chimeric
• 8.3. Human
• 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

• 9.1. Introduction
• 9.2. Autoimmune & Inflammatory Diseases
• 9.3. Hematology
• 9.4. Immunology
• 9.5. Neurology
• 9.6. Oncology
• 9.7. Osteology

10. Antibody Therapeutics Market, by Application

• 10.1. Introduction
• 10.2. Diagnostics
• 10.3. Research
• 10.4. Therapeutics

11. Antibody Therapeutics Market, by End-User

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Research Institutes
• 11.4. Specialty Clinics

12. Americas Antibody Therapeutics Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Antibody Therapeutics Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Antibody Therapeutics Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Numab Therapeutics, secured USD 55 million in funding, increasing its Series C round
  • 15.3.2. Alloy Therapeutics introduced a new licensing model for its ATX-Gx antibody discovery platform
  • 15.3.3. EQT Life Sciences EUR 54 million investment enhances ATB Therapeutics innovative antibody platform
  • 15.3.4. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
  • 15.3.5. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
  • 15.3.6. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
  • 15.3.7. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
  • 15.3.8. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
  • 15.3.9. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
  • 15.3.10. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody
  • 15.3.11. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
  • 15.3.12. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
  • 15.3.13. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
  • 15.3.14. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
  • 15.3.15. Merck to Develop mAb Through USD 10.8 Billion Acquisition
  • 15.3.16. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AbCellera Biologics Inc.
• 3. Adaptimmune Therapeutics PLC
• 4. ADC Therapeutics SA
• 5. Aenova Holding GmbH
• 6. Almac Group Limited
• 7. Amgen Inc.
• 8. Antikor Biopharma
• 9. Argenx SE
• 10. Astellas Pharma Inc.
• 11. AstraZeneca PLC
• 12. Baxter International Inc.
• 13. Bayer AG
• 14. Becton, Dickinson and Company
• 15. Bio-Rad Laboratories, Inc.
• 16. Biogen Inc.
• 17. BioNTech SE
• 18. Bristol-Myers Squibb Company
• 19. Confo Therapeutics
• 20. DH Life Sciences, LLC
• 21. DotBio Pte. Ltd.
• 22. Eli Lilly and Company
• 23. Emergent BioSolutions Inc.
• 24. Evonik Industries AG
• 25. F. Hoffmann-La Roche Ltd.
• 26. GE HealthCare Technologies, Inc.
• 27. Genmab A/S
• 28. GlaxoSmithKline PLC
• 29. Grifols, S.A.
• 30. Incyte Corporation
• 31. iTeos Therapeutics, Inc.
• 32. Johnson & Johnson Services, Inc.
• 33. Merck KGaA
• 34. Merus N.V.
• 35. MoonLake Immunotherapeutics AG
• 36. MorphoSys AG
• 37. Novartis AG
• 38. Novo Nordisk A/S
• 39. Numab Therapeutics AG
• 40. Pfizer Inc.
• 41. PharmAbcine Inc.
• 42. Pyxis Oncology, Inc.
• 43. Regeneron Pharmaceuticals, Inc.
• 44. SAB Biotherapeutics, Inc.
• 45. Sanofi S.A.
• 46. Takeda Pharmaceutical Company Limited
• 47. Thermo Fisher Scientific Inc.
• 48. TRIO Pharmaceuticals Inc.
• 49. UCB S.A.
• 50. Xencor, Inc.